Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials

Taher Abu Hejleh; Laith Abushahin; John Keech; Bryan G Allen; Kalpaj R Parekh; Muhammad Furqan; Mark Iannettoni; Gideon K D Zamba; Sarah L Mott; Gerald Clamon

doi:10.21873/anticanres.12849

Back

Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials

Journal article

Open access

Peer reviewed

Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials

Taher Abu Hejleh, Laith Abushahin, John Keech, Bryan G Allen, Kalpaj R Parekh, Muhammad Furqan, Mark Iannettoni, Gideon K D Zamba, Sarah L Mott and Gerald Clamon

Anticancer research, Vol.38(9), pp.5247-5251

09/2018

DOI: 10.21873/anticanres.12849

PMCID: PMC6651748

PMID: 30194174

Files and links (1)

url

https://doi.org/10.21873/anticanres.12849View

Published (Version of record) Open Access

Abstract

The tolerability of adjuvant chemotherapy in esophageal cancer is unclear. This was a phase II trial of adjuvant paclitaxel in patients with esophageal cancer after trimodality treatment. Patients with residual viable tumor after resection were eligible for study inclusion. Treatment was 80 mg/m paclitaxel intravenously on days 1, 8, and 15 every 28 days for total of two cycles. The primary objective was to determine whether 75% or more of the patients would tolerate 240 mg/m or more of paclitaxel, which corresponded to 50% or more of the total planned dose. Eleven out of the 12 enrolled patients (92%, 95% confidence interval (CI)=62-100%) were able to complete at least 50% of the planned paclitaxel dose. Median progression-free survival was 7 months (95% CI=2-28 months). Median overall survival was 28 months (95% CI=12-36 months). Only one patient experienced a grade 4 adverse event. Screening patients with esophageal cancer after trimodality treatment might improve completion of adjuvant trials.

Drug Administration Schedule

Humans

Middle Aged

Esophagectomy

Paclitaxel - adverse effects

Male

Treatment Outcome

Disease-Free Survival

Antineoplastic Agents, Phytogenic - administration & dosage

Esophageal Neoplasms - surgery

Adult

Female

Aged

Chemotherapy, Adjuvant

Paclitaxel - administration & dosage

Esophageal Neoplasms - drug therapy

Antineoplastic Agents, Phytogenic - adverse effects

Details

Title: Subtitle: Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials
Creators: Taher Abu Hejleh - Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan
Laith Abushahin - Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
John Keech - Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Bryan G Allen - Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Kalpaj R Parekh - Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Muhammad Furqan - Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Mark Iannettoni - Department of Cardiovascular Sciences, Brody School of Medicine at East Carolina University, Greenville, NC, U.S.A
Gideon K D Zamba - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Sarah L Mott - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A
Gerald Clamon - Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, U.S.A. gerald-clamon@uiowa.edu
Resource Type: Journal article
Publication Details: Anticancer research, Vol.38(9), pp.5247-5251
Publisher: Greece
DOI: 10.21873/anticanres.12849
PMID: 30194174
PMCID: PMC6651748
ISSN: 0250-7005
eISSN: 1791-7530
Grant note: P01 CA217797 / NCI NIH HHS
Language: English
Date published: 09/2018
Academic Unit: Radiology; Anatomy and Cell Biology; Hematology, Oncology, and Blood & Marrow Transplantation; Biostatistics; Surgery; Radiation Oncology; Cardiothoracic Surgery; Internal Medicine
Record Identifier: 9984047997002771

Metrics

18 Record Views